Clinical trials: HBP
Ocular Hypertension, Open Angle Glaucoma
Study of AR-13324 in Patients With Elevated Intraocular Pressure
In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days.
- Trial name
- NCT01528787
- Testing
- AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%
- Where
- 11 sites in United States
- Volunteers
- 85 people
- Sponsor
- Aerie Pharmaceuticals
Hypertension
Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat
This was a Phase 1, open-label, single dose study in healthy male subjects. The goals of this clinical trial were to determine how baxdrostat might be absorbed and metabolized using radioactive [14C] labeled baxdrostat.
- Trial name
- NCT05961384
- Testing
- baxdrostat
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Intraabdominal Hypertension, Abdominal Compartment Syndrome
Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry
The Accuryn Registry Study is an open-ended, global, multi-center, retrospective and prospective, single-arm data collection study with an FDA cleared device. The target population are cardiovascular surgery patients.
- Conditions
- Intraabdominal Hypertension, Abdominal Compartment Syndrome, Acute Kidney Injury, Cardiovascular Surgery
- Trial name
- NCT04669548
- Testing
- Accuryn Monitoring System
- Where
- 9 sites in United States
- Volunteers
- 2,500 people
- Sponsor
- Potrero Medical
CHF, Renal Disease
Validation of a Sensor for Non-Invasive Measurements
Subjects will be measured with both a sensor and a reference device
- Conditions
- CHF, Renal Disease, Hypertension
- Trial name
- NCT03463148
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Baxter Healthcare Corporation
Hypertension
Safety and Efficacy of MK0736 & MK0916 in Patients With Hypertension (High Blood Pressure)(0736-003)(COMPLETED)
The objective of this study is to evaluate the safety and efficacy of two investigational drugs (MK-0736 and MK-0916) in lowering blood pressure and body weight in patients with hypertension (high blood pressure).
- Trial name
- NCT00274716
- Testing
- MK0736, MK0916
- Volunteers
- 249 people
- Sponsor
- Merck Sharp & Dohme LLC
Glaucoma
Shunt Tube Exposure Prevention Study
This is a multi-site randomized clinical trial to evaluate the long-term efficacy of the thicker amniotic membrane graft (AmnioGuard™, Bio-Tissue, Inc, Miami, FL) in reducing shunt tube exposure in patients undergoing glaucoma…
- Trial name
- STEPS (NCT01551550)
- Testing
- GDD, Amniotic Membrane Graft, Pericardial Graft
- Where
- 4 sites in United States
- Volunteers
- 82 people
- Sponsor
- BioTissue Holdings, Inc
Hypertension
Withings Devices Follow-up Study - Hypertension
The primary objective is to evaluate the accuracy to predict uncontrolled hypertension with Withings device data.
- Trial name
- NCT06692413
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Withings
Hypertension
Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use
The survey is conducted to collect safety and effectiveness information in Hypertensive patients treated with Micombi Tablets on the long term use in daily clinical settings in Japan.
- Trial name
- NCT01050062
- Testing
- Telmisartan 80mg, Telmisartan 40mg, Hydrochlorothiazide 12.5mg
- Where
- 314 sites in Japan
- Volunteers
- 1,452 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a Day
This study was a multicenter, randomized, PROBE-type (prospective, randomized, open label, blinded end-point) study of 12 weeks duration comprising four visits, carried out in patients with essential arterial hypertension not…
- Trial name
- NCT00700271
- Testing
- Amlodipine, Valsartan
- Where
- 2 sites in France, Tunisia
- Volunteers
- 478 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension
The purpose of this study was to evaluate the dose-response relationships of azilsartan, once daily (QD) in participants with mild to moderate uncomplicated essential hypertension.
- Trial name
- NCT01289132
- Testing
- Azilsartan, Candesartan cilexetil
- Volunteers
- 926 people
- Sponsor
- Takeda
Hypertension
Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension
The purpose of this study is to assess the potential of using valsartan/HCTZ as initial therapy in patients with severe hypertension compared to valsartan alone as initial therapy, and to determine whether a greater proportion of…
- Trial name
- NCT00273299
- Testing
- valsartan plus hydrochlorothiazide
- Where
- United States
- Volunteers
- 607 people
- Sponsor
- Novartis
Pediatric Hypertension With or Without CKD
Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD
To assess efficacy, safety and tolerability of valsartan when comparing two doses of valsartan in reducing and controlling blood pressure in children with hypertension with or without CKD.
- Trial name
- NCT01617681
- Testing
- VAL489
- Where
- 27 sites in Belgium, Brazil and 7 more
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Healthy, Glaucoma
Clinical Validation Study of RTVue Features
To perform a clinical validation study of RTVue features in volunteers with various ocular pathology or no ocular pathology.
- Trial name
- NCT01370850
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Optovue
Uncontrolled Hypertension
Renal Pelvic Denervation Pilot Trial
The RPD Pilot trial will evaluate the safety and effectiveness of Verve Medical's RPDTM renal denervation system for hypertensive patients with uncontrolled blood pressure despite use of two medications at a therapeutic dose.
- Trial name
- NCT07005050
- Testing
- RPD, Active hypertension medical therapy
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Verve Medical, Inc
Hypertension and Dyslipidemia
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386(5)
- Trial name
- NCT05698043
- Testing
- CKD-386(5), D013, D326, D337
- Where
- South Korea
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Renal Disorder
Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)
Antiproteinuric Efficacy of Losartan Potassium in Patients with Non-Diabetic Proteinuric Renal Diseases.
- Trial name
- NCT00140985
- Testing
- MK0954, losartan potassium/Duration of Treatment: 20 weeks, Comparator: amlodipine / Duration of Treatment: 20 weeks
- Volunteers
- 97 people
- Sponsor
- Organon and Co
Glaucoma
A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage
Open-angle glaucoma is the most common type of glaucoma, a disease that damages the nerves in the eye and can lead to vision loss. Current treatments include eye drops, laser treatment, and surgery that help lower eye pressure.
- Trial name
- NCT07770685
- Testing
- ASP2767, Prophylactic Regimen A, Prophylactic Regimen B
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Pulmonary Arterial Hypertension
Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension
The development of selexipag for intravenous administration will be useful to avoid treatment interruptions in patients with pulmonary arterial hypertension (PAH) already treated with selexipag administered orally as tablets…
- Trial name
- NCT03187678
- Testing
- i.v. selexipag, oral selexipag (Uptravi)
- Where
- 8 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- Actelion
Hypertension
Effectiveness of a Digital Health Application for Primary Hypertension (Liebria)
This clinical trial with 328 patients with primary hypertension aims to investigate the effectiveness of the self-guided digital application liebria for patients with primary hypertension.
- Trial name
- NCT06243978
- Testing
- liebria, information brochure on hypertension
- Where
- Germany
- Volunteers
- 328 people
- Sponsor
- Gaia AG
Hypertension, Ischemic Heart Disease
Vibrometer Based Pulse Wave Analysis for Arterial Stiffness and Ischemic Heart Disease Risk Assessment
This clinical investigation will evaluate a novel contactless technology for assessing arterial stiffness and explore its potential in assessment of risk for and development of cardiovascular disease.
- Conditions
- Hypertension, Ischemic Heart Disease, Valvular Heart Disease, Heart Failure
- Trial name
- NCT06984211
- Where
- 3 sites in Sweden
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- HJN Sverige AB/Neko Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.